Rein Therapeutics (RNTX) Stock Price, News & Analysis

Company Overview

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Key Stats

• Today's Range: $1.06 to $1.15
• 50-Day Range: $1.10 to $1.55
• 52-Week Range: $1.04 to $4.40
• Volume: 83,024 shs
• Average Volume: 75,580 shs
• Market Capitalization: $26.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

RNTX Stock Analysis - Frequently Asked Questions

How have RNTX shares performed this year?

Rein Therapeutics' stock was trading at $2.05 at the start of the year. Since then, RNTX stock has decreased by 44.9% and is now trading at $1.13.

How were Rein Therapeutics' earnings last quarter?

Rein Therapeutics Inc. (NASDAQ:RNTX) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.06.

Who are Rein Therapeutics' major shareholders?

Top institutional investors of Rein Therapeutics include BIOS Capital Management LP (7.34%), Voss Capital LP (6.22%), University of Texas Texas AM Investment Management Co. (2.31%) and Cable Car Capital LP (1.82%).

How do I buy shares of Rein Therapeutics?

Shares of RNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNTX
• CIK: 1420565
• Web: N/A
• Phone: (737) 802-1989
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -141.11%
• Return on Assets: -33.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.46 per share
• Price / Cash Flow: 2.46
• Book Value: $0.13 per share
• Price / Book: 8.69

Miscellaneous

• Outstanding Shares: 23,310,000
• Free Float: 22,116,000
• Market Cap: $26.34 million
• Optionable: N/A
• Beta: 1.31